Efficacy of recombinant human epidermal growth factor plus sodium hyaluronate eye drops in diabetic dry eye post-cataract surgery

Table 1 General data, n (%)

Factors	Observation group (n = 42)	Control group (n = 40)	t/χ2	P value
Sex			0.001	0.991
Male	22 (52.38)	21 (52.50)
Female	20 (47.62)	19 (47.50)
Age (yr)			0.002	0.965
≤ 61	17 (40.48)	16 (40.00)
> 61	25 (59.52)	24 (60.00)
BMI (kg/m2)			0.001	0.983
≤ 23	23 (54.76)	22 (55.00)
> 23	19 (45.24)	18 (45.00)
Mean course of disease (months)	4.65 ± 0.85	4.82 ± 0.81	0.926	0.357
Hypertension			0.001	0.991
Yes	20 (47.62)	19 (47.50)
No	22 (52.38)	21 (52.50)
Smoking history			0.002	0.965
Yes	25 (59.52)	24 (60.00)
No	17 (40.48)	16 (40.00)

BMI: Body mass index.

Table 2 Comparison of therapeutic efficacy, n (%)

Therapeutic effect	Observation group (n = 42)	Control group (n = 40)	χ2	P value
Cure	24 (57.14)	14 (35.00)
Marked effectiveness	10 (23.81)	10 (25.00)	-	-
Effectiveness	6 (14.29)	4 (10.00)	-	-
Ineffectiveness	2 (4.76)	12 (30.00)	-	-
Total effective rate	40 (95.24)	28 (70.00)	9.217	0.002

Table 3 Comparison of adverse reaction rates, n (%)

Adverse reactions	Observation group (n = 42)	Control group (n = 40)	χ2	P value
Conjunctival hyperemia	2 (4.76)	1 (2.50)	-	-
Aggravated lacrimal gland injury	1 (2.38)	1 (2.50)	-	-
Local inflammation	0	1 (2.50)	-	-
Corneal erosion	2 (4.76)	2 (5.00)	-	-
Adverse reaction rate	5 (11.90)	5 (12.50)	0.007	0.934

Table 4 Comparison of treatment satisfaction

Satisfaction	Observation group (n = 42)	Control group (n = 40)	χ2	P value
Very satisfied	30 (71.43)	19 (47.50)	-	-
Satisfied	11 (26.19)	10 (25.00)	-	-
Dissatisfied	1 (2.38)	11 (27.50)	-	-
Treatment satisfaction	41 (97.62)	29 (72.50)	10.35	0.001